A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P.
Gamucci T, et al. Among authors: angelini f.
J Cell Physiol. 2017 Jun;232(6):1571-1578. doi: 10.1002/jcp.25685. Epub 2016 Nov 30.
J Cell Physiol. 2017.
PMID: 27861874
Free PMC article.